Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Significance: Age-related bioenergetic insufficiency increases the vulnerability of retinal ganglion cells to intraocular pressure during glaucoma pathogenesis. This paper addresses these relationships and provides a deeper understanding of this common neurodegeneration. We demonstrate an intraocular pressure-dependent decline in retinal pyruvate levels coupled to dysregulated glucose metabolism, and detected mTOR activation at the mechanistic nexus of neurodegeneration and metabolism. Supporting this, oral supplementation of pyruvate or mTOR inhibition by rapamycin strongly protects from neurodegeneration. Bioenergetic enhancement thus provides a readily clinically translatable strategy for neurodegenerative disease. This study provides important avenues for neuroprotection against glaucoma by targeting key metabolic pathways that may be mirrored in other neurodegenerative diseases in which metabolic dysregulation may play a key role.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. Pyruvate protects from glaucomatous neurodegeneration in chronic mouse and rat models. (A–I) DBA/2J mice. (A) Retinal pyruvate levels decline following the onset of elevated IOP and are recovered by oral pyruvate treatment (n > 24/group). (B and H) Pyruvate intervention protected from optic nerve degeneration as assessed by PPD staining (paraphenylenediamine; a sensitive stain for damaged axons) in D2 mice (n = 60/group). Green, no or early damage (<5% axon loss; no or early [NOE]); yellow, moderate damage (∼30% axon loss [MOD]); red, severe (>50% axon loss [SEV]) damage. (C) Counts and (D) optic nerve areas from D2 mice demonstrate a robust axon protection by pyruvate treatment (control = no glaucoma, D2-Gpnmb+; n = 10/group; all NOE except for D2 which are SEV). (E and H) Pyruvate protected from RGC soma loss (RBPMS is a specific marker of RGCs in the retina; control = D2. Gpnmb+; n = 6/group). (F and G) Pyruvate rescued PERG amplitude so that 12-mo-old treated mice were not significantly different from 9-mo-old untreated mice that had not yet developed glaucomatous degeneration (PERG is a sensitive measure of RGC function in animals and humans; n > 20/group). Individual example tracings are shown in G. (I) Pyruvate protects from the loss of anterograde axoplasmic transport as assessed by CT-β tracing to the dLGN (dorsal lateral geniculate nucleus) and SC (superior colliculus) (control = D2-Gpnmb+; n = 6/group; quantification shown to the Right). (J–O) Inducible rat model. (J) Laser photocoagulation of limbal blood vessels in rats caused a subacute elevation of IOP (ocular hypertension [OHT]). The magnitude of IOP elevation is unchanged by pyruvate treatment. (K and L) Pyruvate treatment in the rat prevents RGC soma loss and axon loss in the optic nerve. Examples are shown in O. Brn3a is a specific marker of RGCs in the rat retina. (M–O) Pyruvate treatment decreases RGC axon cytoskeletal damage (SMI32+ dystrophic axons) and decreases microglia activation (ED1+ microglia) (n = 18/group for J–O). *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.](https://figures.cochat.ai/paper-figures/328e09583dd5481daeacb0b150e82a52/disturbed-glucose-and-pyruvate-metabolism-in-glaucoma-with-neuroprotection-by-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our results contrast with previous findings showing that the mTOR inhibitor rapamycin promoted RGC survival [63].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · cited 3×
“Rapamycin is an mTOR inhibitor that promotes survival mechanisms associated with fasting and decreased energy use (34).”
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., Fan, T. W.-M., Fiehn, O., Goodacre, R., Griffin, J. L., et al. (2007) · Metabolomics · doi:10.1007/s11306-007-0082-2 · Cited by 5,368 · cited 3×
“Metabolite identities were confirmed according to level 1 of the Metabolomics Standards Initiative (16). mTOR Phospho Antibody Array. mTOR phospho antibody arrays were performed on n = 3 per condition of whole homogenized retina from 9 mo of age D2 and D2-Gpnmb + mice following the manufacturer ’ s…”
InfluentialMetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
Chong, J., Soufan, O., Li, C., Caraus, I., Li, S., Bourque, G., Wishart, D. S., & Xia, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky310 · Cited by 3,629 · cited 1×
“Metabolomics data were analyzed using MetaboAnalyst and R using the 86 identified metabolites as a background list for enrichment (49, 50).”
Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis
Chong, J., Wishart, D. S., & Xia, J. (2019) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.86 · Cited by 2,166 · cited 1×
“Metabolomics data were analyzed using MetaboAnalyst and R using the 86 identified metabolites as a background list for enrichment (49, 50).”
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481 · cited 2×
“Animals were excluded from further analysis if severe hyphema developed subsequent to laser treatment [29% collectively, which was lower than the hyphema rate of 40% reported by Levkovitch-Verbin et al. (38)].”
Use of within-array replicate spots for assessing differential expression in microarray experiments
Smyth, G. K., Michaud, J., & Scott, H. S. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti270 · Cited by 1,405 · cited 1×
“Data were analyzed in R using limma (linear models for microarray data, designed for microarray analysis but suitable for other data types) (51 – 53).”
Birsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388 · cited 1×
“One is a pyruvate-induced increase in NAD availability to NAD-consuming enzymes that generate NAM (e.g., PARPs and SIRTs; although pyruvate doesn ’ t directly produce NAD in these reactions) (26, 27).”
NAD + in aging, metabolism, and neurodegeneration
Verdin, E. (2015) · Science · doi:10.1126/science.aac4854 · Cited by 1,319 · cited 1×
“One is a pyruvate-induced increase in NAD availability to NAD-consuming enzymes that generate NAM (e.g., PARPs and SIRTs; although pyruvate doesn ’ t directly produce NAD in these reactions) (26, 27).”
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · cited 1×
“1 C ), further experiments are required to more precisely dissect these pathways in the context of disease (36).”
Regulation of pyruvate metabolism and human disease
Gray, L. R., Tompkins, S. C., & Taylor, E. B. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1539-2 · Cited by 947
Vitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
Williams, P. A., Harder, J. M., Foxworth, N. E., Cochran, K. E., Philip, V. M., Porciatti, V., Smithies, O., & John, S. W. M. (2017) · Science · doi:10.1126/science.aal0092 · Cited by 617 · cited 10×
“Micewerehousedina14-hlight/10-h dark cycle with food and water available ad libitum as previously reported (7).”
InfluentialSelf-citationEssential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice.
John, S. W. M., Smith, R. S., Savinova, O. V., Hawes, N. L., Chang, B., Turnbull, D., Davisson, M. T., Roderick, T. H., & Heckenlively, J. R. (1998) · PubMed · Cited by 603
Self-citationEvidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507 · cited 1×
“Elevated glucose is associated with poor outcomes in brain injury and disease (17, 18), and high glucose concentrations lead to decreased mitochondrial cristae and mitochondrial remodeling in diabetic and cell models (19, 20).”
Safety of high-dose nicotinamide: a review
Knip, M., Douek, I. F., Moore, W. P. T., Gillmor, H. A., McLean, A. E. M., Bingley, P. J., & Gale, E. A. M. (2000) · Diabetologia · doi:10.1007/s001250051536 · Cited by 422 · cited 1×
“Pyruvate and NAM are ideal treatments for clinical use, with long histories and favorable safety profiles in humans (5, 33).”
Oxidative stress and mitochondrial dysfunction in glaucoma
Chrysostomou, V., Rezania, F., Trounce, I. A., & Crowston, J. G. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.008 · Cited by 403 · cited 1×
“In addition to a major role in energy metabolism, pyruvate has been shown to protect against PARP activation, oxidative stress, and neuroinflammation (10, 11), all of which have been associated with glaucoma (12 – 15).”
Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats.
Levkovitch-Verbin, H., Quigley, H. A., Martin, K. R. G., Valenta, D. F., Baumrind, L. A., & Pease, M. E. (2002) · PubMed · Cited by 365
Empirical array quality weights in the analysis of microarray data
Ritchie, M. E., Diyagama, D., Neilson, J., van Laar, R., Dobrovic, A., Holloway, A., & Smyth, G. K. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-261 · Cited by 312
Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis
Andrabi, S. A., Umanah, G. K. E., Chang, C., Stevens, D. A., Karuppagounder, S. S., Gagné, J.-P., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405158111 · Cited by 307 · cited 2×
“In addition to a major role in energy metabolism, pyruvate has been shown to protect against PARP activation, oxidative stress, and neuroinflammation (10, 11), all of which have been associated with glaucoma (12 – 15).”
Characterization of Susceptibility of Inbred Mouse Strains to Diabetic Nephropathy
Qi, Z., Fujita, H., Jin, J., Davis, L. S., Wang, Y., Fogo, A. B., & Breyer, M. D. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2628 · Cited by 297 · cited 1×
“D2 mice do not have hyperglycemia (21, 22), implying that retinal glucose metabolism itself is disrupted.”
Neuroinflammation in glaucoma: A new opportunity
Williams, P. A., Marsh-Armstrong, N., Howell, G. R., Bosco, A., Danias, J., Simon, J., Di Polo, A., Kuehn, M. H., Przedborski, S., Raff, M., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.02.014 · Cited by 253
Self-citationHowell, G. R., Soto, I., Zhu, X., Ryan, M., Macalinao, D. G., Sousa, G. L., Caddle, L. B., MacNicoll, K. H., Barbay, J. M., Porciatti, V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61135 · Cited by 232 · cited 1×
“In addition to a major role in energy metabolism, pyruvate has been shown to protect against PARP activation, oxidative stress, and neuroinflammation (10, 11), all of which have been associated with glaucoma (12 – 15).”
Self-citationLifetime Risk of Blindness in Open-Angle Glaucoma
Peters, D., Bengtsson, B., & Heijl, A. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.027 · Cited by 198 · cited 1×
“Subsequently, > 40% of treated glaucoma patients will go blind in at least one eye (2), highlighting the therapeutic need for new neuroprotective strategies.”
Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods
(2001) · CRC Press eBooks · doi:10.1201/9781420041606 · Cited by 195
Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain
Mancino, R., Martucci, A., Cesareo, M., Giannini, C., Corasaniti, M. T., Bagetta, G., & Nucci, C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666171206144045 · Cited by 165 · cited 1×
“Although the factors that initiate glaucomatous neurodegeneration remain to be elucidated, they are unlikely to be unique to glaucoma (3, 4).”
Review: Traumatic brain injury and hyperglycemia, a potentially modifiable risk factor
Shi, J., Dong, B., Mao, Y., Guan, W., Cao, J., Zhu, R., & Wang, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11958 · Cited by 162
Naz, S., Gallart-Ayala, H., Reinke, S. N., Mathon, C., Blankley, R., Chaleckis, R., & Wheelock, C. E. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b00925 · Cited by 143 · cited 1×
“For further details regarding the acquisition methodology, see Naz et al. (47) and Daskalaki et al. (48).”
Self-citationZheng, X., Boyer, L., Jin, M., Kim, Y., Fan, W., Bardy, C., Berggren, T., Evans, R. M., Gage, F. H., & Hunter, T. (2016) · eLife · doi:10.7554/elife.13378 · Cited by 136
Saleh, M., Nagaraju, M., & Porciatti, V. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0483 · Cited by 127 · cited 1×
“PERG was recorded subcutaneously (s.c.) from the snout of mice as previously reported (7, 39).”
Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods
Gossman, M. V. (2004) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-200403000-00021 · Cited by 119 · cited 1×
“The processing of optic nerves and staining with paraphenylenedi-amine (PPD) was as published (41).”
Nicotinamide Deficiency in Primary Open-Angle Glaucoma
Kouassi Nzoughet, J., Chao de la Barca, J. M., Guehlouz, K., Leruez, S., Coulbault, L., Allouche, S., Bocca, C., Muller, J., Amati-Bonneau, P., Gohier, P., et al. (2019) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.19-27099 · Cited by 110
Nicotinamide and WLDS Act Together to Prevent Neurodegeneration in Glaucoma
Williams, P. A., Harder, J. M., Foxworth, N. E., Cardozo, B. H., Cochran, K. E., & John, S. W. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00232 · Cited by 108 · cited 1×
“NAM supplementation prevents age-dependent decreases in NAD levels, transcriptional reprogramming of RGCs, mitochondrial decline, and RGC neurodegeneration (5, 7, 24, 25).”
Self-citationAlzheimer’s Disease and Glaucoma: Mechanistic Similarities and Differences
Ghiso, J. A. (2013) · Journal of Glaucoma · doi:10.1097/ijg.0b013e3182934af6 · Cited by 107 · cited 1×
“Although the factors that initiate glaucomatous neurodegeneration remain to be elucidated, they are unlikely to be unique to glaucoma (3, 4).”
Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams, P. A., Harder, J. M., & John, S. W. M. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000767 · Cited by 102 · cited 5×
“Pyruvate and NAM are ideal treatments for clinical use, with long histories and favorable safety profiles in humans (5, 33).”
InfluentialSelf-citationNicotinamide treatment robustly protects from inherited mouse glaucoma
Williams, P. A., Harder, J. M., Cardozo, B. H., Foxworth, N. E., & John, S. W. M. (2018) · Communicative & Integrative Biology · doi:10.1080/19420889.2017.1356956 · Cited by 96 · cited 1×
“NAM supplementation prevents age-dependent decreases in NAD levels, transcriptional reprogramming of RGCs, mitochondrial decline, and RGC neurodegeneration (5, 7, 24, 25).”
Self-citationMetabolic Vulnerability in the Neurodegenerative Disease Glaucoma
Inman, D. M., & Harun-Or-Rashid, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00146 · Cited by 88 · cited 2×
“Age-and intraocular pressure-dependent metabolic deficits are emerging as a critical factor influencing RGC vulnerability in glaucoma (5, 6).”
Inhibition of monocyte-like cell extravasation protects from neurodegeneration in DBA/2J glaucoma
Williams, P. A., Braine, C. E., Kizhatil, K., Foxworth, N. E., Tolman, N. G., Harder, J. M., Scott, R. A., Sousa, G. L., Panitch, A., Howell, G. R., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0303-3 · Cited by 79
Self-citationChou, T.-H., Bohorquez, J., Toft-Nielsen, J., Ozdamar, O., & Porciatti, V. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-13943 · Cited by 74 · cited 1×
“Waveforms were retrieved using an asynchronous averaging method (40).”
A unique array of neuroprotective effects of pyruvate in neuropathology
Zilberter, Y., Gubkina, O., & Ivanov, A. I. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00017 · Cited by 64 · cited 2×
“In addition to a major role in energy metabolism, pyruvate has been shown to protect against PARP activation, oxidative stress, and neuroinflammation (10, 11), all of which have been associated with glaucoma (12 – 15).”
Mitochondrial Structural Changes in the Pathogenesis of Diabetic Retinopathy
Roy, S., Kim, D., & Sankaramoorthy, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091363 · Cited by 55 · cited 1×
“Elevated glucose is associated with poor outcomes in brain injury and disease (17, 18), and high glucose concentrations lead to decreased mitochondrial cristae and mitochondrial remodeling in diabetic and cell models (19, 20).”
Ebneter, A. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.269 · Cited by 54 · cited 1×
“Quantification of immunolabeling for each marker in longitudinal sections of the intracranial optic nerve was performed as previously described (43).”
Ma, R., Wu, Y., Zhai, Y., Hu, B., Ma, W., Yang, W., Yu, Q., Chen, Z. B., Workman, J. L., Yu, X., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz864 · Cited by 53
Neuroprotection in glaucoma: present and future
CHEN, S.-D., WANG, L., & ZHANG, X.-L. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20123565 · Cited by 50
Automated Axon Counting in Rodent Optic Nerve Sections with AxonJ
Zarei, K., Scheetz, T. E., Christopher, M. A., Miller, K., Hedberg‐Buenz, A., Tandon, A., Anderson, M. G., Fingert, J. H., & Abràmoff, M. D. (2016) · Scientific Reports · doi:10.1038/srep26559 · Cited by 50 · cited 1×
“Optic nerve axon counts were performed using AxonJ (42).”
Daskalaki, E., Pillon, N. J., Krook, A., Wheelock, C. E., & Checa, A. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.034 · Cited by 43 · cited 1×
“For further details regarding the acquisition methodology, see Naz et al. (47) and Daskalaki et al. (48).”
Self-citationDlasková, A., Engstová, H., Špaček, T., Kahancová, A., Pavluch, V., Smolková, K., Špačková, J., Bartoš, M., Plecitá‐Hlavatá, L., & Ježek, P. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.04.013 · Cited by 42 · cited 1×
“Elevated glucose is associated with poor outcomes in brain injury and disease (17, 18), and high glucose concentrations lead to decreased mitochondrial cristae and mitochondrial remodeling in diabetic and cell models (19, 20).”
Expression and distribution of peroxiredoxins in the retina and optic nerve
Chidlow, G., Wood, J. P. M., Knoops, B., & Casson, R. J. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1135-3 · Cited by 41
Self-citationJassim, A. H., Coughlin, L., Harun‐Or‐Rashid, M., Kang, P. T., Chen, Y., & Inman, D. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1576-4 · Cited by 35 · cited 2×
“Hif1 α is increased in the retinas of D2 mice following high IOP (7) and D2 optic nerves have a decreased maximal respiratory rate and altered glycolytic responses (30).”
Glutamine as an energy substrate in cultured neurons during glucose deprivation
Peng, L., Gu, L., Zhang, H., Huang, X., Hertz, E., & Hertz, L. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21262 · Cited by 31 · cited 1×
“Glutamine was present in this case because removal of all nutrients caused catastrophic death of all cells within 2 to 4 h and this amino acid has been shown to support neuron survival in vitro (46).”
Wood, J. P. M., Mammone, T., Chidlow, G., Greenwell, T., & Casson, R. J. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9171 · Cited by 25 · cited 1×
“Cultures were prepared via a sequential trypsin-and mechanical-digest procedure and comprised neurons, including RGCs, glia, and photoreceptors, as previously described (45).”
Self-citationDBA/2J Mice Are Susceptible to Diabetic Nephropathy and Diabetic Exacerbation of IOP Elevation
Soto, I., Howell, G. R., John, C. W., Kief, J. L., Libby, R. T., & John, S. W. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107291 · Cited by 20 · cited 1×
“D2 mice do not have hyperglycemia (21, 22), implying that retinal glucose metabolism itself is disrupted.”
Self-citationSakaguchi, T., Kuno, M., & Kawasaki, K. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00023-8 · Cited by 16 · cited 1×
“It is an antioxidant and modulates the pentose phosphate pathway and hence glutathione metabolism, which is also changed by pyruvate treatment (31, 32).”
Gluconate suppresses seizure activity in developing brains by inhibiting CLC-3 chloride channels
Wu, Z., Huo, Q., Ren, L., Dong, F., Feng, M., Wang, Y., Bai, Y., Lüscher, B., Li, S.-T., Wang, G.-L., et al. (2019) · Molecular Brain · doi:10.1186/s13041-019-0465-0 · Cited by 9 · cited 1×
“It is an antioxidant and modulates the pentose phosphate pathway and hence glutathione metabolism, which is also changed by pyruvate treatment (31, 32).”
Cited by
Tezel, G. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100998 · Cited by 163
Moraes, C. G. D., John, S. W. M., Williams, P. A., Blumberg, D. M., Cioffi, G. A., & Liebmann, J. M. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.4576 · Cited by 180
Self-citationMarchev, A. S., Mihaylova, L. V., Amirova, K. M., Savova, M. S., Balcheva-Sivenova, Z. P., & Georgiev, M. I. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03918-3 · Cited by 180
Adaptive responses to neurodegenerative stress in glaucoma
Calkins, D. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100953 · Cited by 126
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering
Tribble, J. R., Hui, F., Quintero, H., Hajji, S. E., Bell, K. C., Polo, A. D., & Williams, P. A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101193 · Cited by 137
Self-citation
Metadata
- Authors
- Harder, J. M., Guymer, C., Wood, J. P. M., Daskalaki, E., Chidlow, G., Zhang, C., Balasubramanian, R., Cardozo, B. H., Foxworth, N. E., Deering, K. E., Ouellette, T. B., Montgomery, C., Wheelock, C. E., Casson, R. J., Williams, P. A., & John, S. W. M.
- Affiliations
- Jackson Laboratory (US)
- The University of Adelaide (AU)
- Karolinska Institutet (SE)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Williams, Pete A.
- John, Simon W. M.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-12-14
- Volume
- 117
- Issue
- 52
- Pages
- 33619-33627
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7776900
- OpenAlex
- W3112239941
- Cited by
- 127
- References
- 54
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 24 · 2023: 19 · 2022: 16 · 2021: 20
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- Vetenskapsrådet (2018-02124)
- HHS | NIH | National Eye Institute (EY011721)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- glaucoma, retinal ganglion cell death, intraocular pressure, glucose metabolism, pyruvate metabolism, glycolysis, mTOR signaling, rapamycin, neuroprotection, DBA/2J mice, optic nerve degeneration, glycogen mobilization
- MeSH terms
- Neuroprotection, Animals, Disease Models, Animal, Glaucoma, Glucose, Intraocular Pressure, Mice, Inbred C57BL, Mice, Inbred DBA, Nerve Degeneration, Retina, Rats, Sprague-Dawley, Neuroprotective Agents, Pyruvic Acid, Sirolimus, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.